- Home
- AEF vs IMMP Comparison
AEF vs IMMP Comparison
Compare AEF & IMMP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AEF
- IMMP
- Stock Information
- Founded
- AEF 1989
- IMMP 1987
- Country
- AEF United States
- IMMP Australia
- Employees
- AEF N/A
- IMMP N/A
- Industry
- AEF Finance/Investors Services
- IMMP Biotechnology: Pharmaceutical Preparations
- Sector
- AEF Finance
- IMMP Health Care
- Exchange
- AEF Nasdaq
- IMMP Nasdaq
- Market Cap
- AEF 237.5M
- IMMP 244.5M
- IPO Year
- AEF N/A
- IMMP N/A
- Fundamental
- Price
- AEF $6.03
- IMMP $1.78
- Analyst Decision
- AEF
- IMMP Buy
- Analyst Count
- AEF 0
- IMMP 1
- Target Price
- AEF N/A
- IMMP $7.00
- AVG Volume (30 Days)
- AEF 92.5K
- IMMP 69.1K
- Earning Date
- AEF 01-01-0001
- IMMP 02-27-2025
- Dividend Yield
- AEF 7.13%
- IMMP N/A
- EPS Growth
- AEF N/A
- IMMP N/A
- EPS
- AEF 0.57
- IMMP N/A
- Revenue
- AEF N/A
- IMMP $3,019,249.00
- Revenue This Year
- AEF N/A
- IMMP $50.37
- Revenue Next Year
- AEF N/A
- IMMP N/A
- P/E Ratio
- AEF $8.86
- IMMP N/A
- Revenue Growth
- AEF N/A
- IMMP 24.11
- 52 Week Low
- AEF $4.40
- IMMP $1.32
- 52 Week High
- AEF $5.53
- IMMP $2.72
- Technical
- Relative Strength Index (RSI)
- AEF 57.56
- IMMP 57.37
- Support Level
- AEF $5.86
- IMMP $1.60
- Resistance Level
- AEF $6.22
- IMMP $1.83
- Average True Range (ATR)
- AEF 0.10
- IMMP 0.05
- MACD
- AEF -0.01
- IMMP 0.02
- Stochastic Oscillator
- AEF 56.41
- IMMP 76.09
About AEF abrdn Emerging Markets Equity Income Fund Inc.
ABERDEEN EMERGING MARKETS EQUITY INCOME FUND, INC. is a closed-end investment company. The Fund's investment objective is to seek to provide both current income and long-term capital appreciation. The Fund invests in a range of sectors, including financials, consumer staples, utilities, consumer discretionary, materials, energy, information technology, private equity, communication services, healthcare, real estate, and industrials.
About IMMP Immutep Limited
Immutep Ltd is a globally active biotechnology company developing immunotherapy products for cancer and autoimmune diseases. Its main product is IMP321, which involves clinical development for the treatment of cancer indications. The company is also focused on the development of other products, which include IMP701, which is a blocking anti-LAG-3 antibody for cancer and is in Phase I of its clinical trials, and CVac, which is a personalized immunocellular therapeutic investigated for the treatment of epithelial cancer. Geographically all the business activity of the firm is functioned through the region of Australia.